Arena Pharmaceuticals Has Preclinical Data at Pain World Congress

Arena Pharmaceuticals, Inc., Inc. (Nasdaq: ARNA) today announced that results from preclinical studies of its investigative drug candidate olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor 2 (CB₂) in development for the treatment of visceral pain associated with Crohn’s disease, were presented at the International Association for the Study of Pain (IASP) World Congress in Boston, MA.

“We are pleased to present data supporting olorinab’s antinociceptive effects in visceral sensory pathways,” said Preston Klassen, MD, MHS, Executive Vice President, Research and Development and Chief Medical Officer of Arena. “Through its full-agonism and selectivity, we believe olorinab may provide a novel therapeutic approach for sustained relief of visceral pain without psychotropic effects, potentially providing a new treatment option without the risk for dependence or abuse. We are currently evaluating olorinab in a Phase 2 clinical trial in IBD-associated abdominal pain and expect the availability of topline data by the end of the third quarter.”

Presentation Details
Poster Abstract Title: APD371, a Peripherally Restricted, Highly Selective, Full Agonist of the Cannabinoid Receptor 2 (CB2) Receptor, Reduces Colitis-Induced Visceral Hypersensitivity in Rats
Poster Number: PFR455
Presentation Date: Friday, September 14

https://www.biospace.com/article/releases/arena-pharmaceuticals-presents-preclinical-data-for-olorinab-at-international-association-for-the-study-of-pain-world-congress/